Fibrodysplasia ossificans progressiva is a rare genetic condition that transforms muscle and connective tissue into bone over time. This progressive disorder creates a second skeleton outside the body’s normal framework, severely limiting movement and requiring specialized approaches to manage symptoms and slow its advancement. Understanding treatment options—from standard supportive care to experimental therapies in clinical trials—is essential for those living with this challenging condition.

Managing a Condition That Turns Soft Tissue Into Bone

Treatment for fibrodysplasia ossificans progressiva focuses on several interconnected goals that shape daily medical care. The primary aim is controlling painful episodes known as flare-ups, which occur when soft tissues swell and eventually harden into bone. Managing these episodes can help reduce the rate at which new bone forms outside the skeleton. Another key goal involves preserving mobility for as long as possible, since each bout of heterotopic ossification—the medical term for bone forming in places where it should not exist—can permanently restrict movement in affected joints.^[1]

The approach to treatment varies significantly depending on the stage of the disease and individual patient characteristics. Children diagnosed early may benefit from preventive strategies that avoid trauma and minimize flare-ups, while adults with more advanced disease require adaptations to maintain quality of life despite increasing physical limitations. Medical societies specializing in rare genetic disorders have established guidelines based on collective expertise from international specialists, though the extreme rarity of the condition means that much knowledge comes from careful observation rather than large-scale studies.^[13]

Beyond established treatments approved by regulatory authorities, ongoing research explores innovative therapies through clinical trials. These investigations test new molecular approaches that target the underlying genetic defect causing abnormal bone formation. Patients and families should understand that standard treatments focus on symptom management and prevention of complications, while experimental approaches aim to address the disease mechanism itself. The decision to pursue any treatment path requires careful consultation with physicians experienced in managing this ultra-rare condition, as even routine medical procedures can trigger dangerous flare-ups if not performed correctly.^[4]

Standard Treatment Approaches for Symptom Control

The foundation of standard treatment rests on preventing and managing flare-ups, those painful episodes when muscle tissue begins transforming into bone. When a flare-up occurs—often triggered by falls, viral illnesses like influenza, or any trauma to soft tissues—the affected area swells significantly and becomes inflamed. This myositis, or muscle inflammation, can last from days to several months before the tissue hardens into permanent bone. Medical teams typically respond to flare-ups with anti-inflammatory medications to reduce swelling and discomfort during these critical periods.^[1][2]

Corticosteroid medications represent the most commonly used anti-inflammatory drugs during acute flare-ups. These medications work by dampening the body’s inflammatory response, potentially reducing the severity of bone formation if started early enough in an episode. Doctors typically prescribe these drugs for short periods during active flare-ups rather than as long-term maintenance therapy. The specific dosing and duration depend on the location and severity of the episode, with careful monitoring required to balance symptom relief against potential side effects from steroid use.^[10]

Beyond medications for acute episodes, standard care emphasizes prevention through lifestyle modifications and careful activity management. Patients are encouraged to remain active within safe limits, avoiding contact sports or activities that risk falls and injuries. Water-based exercises prove particularly beneficial because they allow movement without risk of hard impacts. Singing and breathing exercises help maintain chest wall mobility, which is critical since bone formation around the rib cage can restrict lung expansion and lead to breathing difficulties. These respiratory exercises become increasingly important as the disease progresses and chest movement becomes more limited.^[13]

The duration of standard therapy extends throughout a patient’s lifetime, though the specific interventions change as the disease advances. Early in the disease, treatment focuses heavily on prevention and education about avoiding triggers. As more joints become affected by heterotopic ossification, supportive care becomes increasingly important. This includes adaptations to living spaces, assistive devices for eating and daily activities, and nutritional support when jaw involvement makes chewing difficult. Physical therapy must be approached with extreme caution—passive range of motion exercises, where someone else moves the patient’s joints, are strictly contraindicated because they can trigger new bone formation. Only gentle, patient-controlled movements are considered safe.^[10]

Side effects from the medications used in standard treatment primarily relate to the corticosteroids employed during flare-ups. Short-term use can cause increased appetite, mood changes, difficulty sleeping, and elevated blood sugar levels. When used repeatedly over time, as may be necessary given the recurrent nature of flare-ups, these drugs can contribute to bone weakness in the normal skeleton (ironically, even as abnormal bone forms elsewhere), weight gain, and increased susceptibility to infections. This reality requires doctors to carefully weigh the benefits of reducing inflammation against the risks of medication side effects, individualizing treatment based on each patient’s specific circumstances and the severity of their flare-ups.^[10]

Emerging Therapies Under Investigation in Clinical Trials

Research into fibrodysplasia ossificans progressiva has accelerated significantly following the discovery in 2006 that mutations in the ACVR1 gene cause the condition. This breakthrough opened pathways for developing targeted therapies that address the underlying molecular problem rather than simply managing symptoms. The ACVR1 gene provides instructions for making a receptor protein that responds to bone morphogenetic proteins, or BMPs. In people with the condition, mutations cause this receptor to become overactive, sending excessive signals that instruct soft tissues to transform into bone. Understanding this mechanism has allowed researchers to design molecules that could potentially block this inappropriate signaling.^[1][8]

One of the most advanced experimental treatments currently under investigation is palovarotene, a drug that has progressed through multiple phases of clinical testing. This medication belongs to a class of compounds called retinoic acid receptor gamma agonists. It works by interfering with the early stages of cartilage formation that precede bone development. By binding to specific receptors involved in skeletal development, palovarotene aims to prevent the process of endochondral ossification—the normal mechanism by which the body forms bone, but which occurs inappropriately in fibrodysplasia ossificans progressiva. Early-phase trials evaluated the drug’s safety profile in small groups of patients, while later studies examined whether it could reduce the volume of new heterotopic bone formed during and after flare-ups.^[3]

Phase II clinical trials for palovarotene focused on establishing whether the drug actually affects the disease process in meaningful ways. These studies enrolled patients with confirmed ACVR1 mutations and monitored them carefully during flare-up episodes. Researchers used advanced imaging techniques to measure the amount of new bone formation when patients took palovarotene compared to historical data. Preliminary results from these trials suggested that treated patients might develop less new heterotopic bone during flare-ups than would typically be expected based on the natural history of the disease. The drug’s mechanism targets a key step in bone formation, potentially interrupting the cascade of cellular events that leads from inflammation to permanent ossification.^[9]

Phase III trials represent the most rigorous testing stage, comparing new treatments directly against standard care or placebo in larger patient populations. For palovarotene, these advanced studies have enrolled patients from multiple countries, including sites in the United States, Europe, and other regions. The international scope reflects both the global nature of research into rare diseases and the need to gather sufficient patient numbers given how uncommon fibrodysplasia ossificans progressiva is. Eligibility for these trials typically requires genetic confirmation of the ACVR1 mutation, documentation of previous flare-ups, and the ability to travel to specialized centers with expertise in the condition. Trial participants undergo regular monitoring, including imaging studies to track bone formation and careful clinical assessments of mobility and function.^[3]

Beyond palovarotene, researchers are exploring other innovative molecular approaches in earlier-stage investigations. Some teams are studying antisense oligonucleotide therapy, a technique that uses specially designed genetic molecules to reduce the production of the mutated ACVR1 protein. These antisense molecules work by binding to the genetic instructions (messenger RNA) that cells use to manufacture the problematic receptor, effectively turning down its production. Phase I studies for such approaches focus primarily on safety, testing whether the genetic medicine can be delivered safely and determining appropriate doses before examining effectiveness.^[9]

Another avenue of investigation involves antibody-based therapies designed to block the activity of activin A, a protein that inappropriately activates the mutated ACVR1 receptor in fibrodysplasia ossificans progressiva. By developing antibodies that bind to and neutralize activin A, researchers hope to prevent the receptor from receiving signals that trigger bone formation. These antibody therapies must be given by injection or infusion, and early-phase trials assess how frequently dosing is needed and whether blocking activin A produces unacceptable side effects elsewhere in the body, since this protein has normal functions in tissues throughout the body.^[9]

The side effects observed in clinical trials vary depending on the specific therapy being tested. For palovarotene, early reports from trials indicated some patients experienced temporary changes in bone growth plates—the areas where normal bones lengthen during childhood and adolescence. This raised particular concerns about use in children and adolescents whose skeletons are still developing. Other reported side effects included headaches, dry skin and lips, and temporary increases in certain fat levels in the blood. These effects, typical of drugs related to vitamin A compounds, generally resolved when treatment was paused or the dose adjusted. Researchers continue monitoring patients long-term to understand whether these medications have delayed effects that only appear after extended use.^[3]

Clinical trial locations for fibrodysplasia ossificans progressiva studies span multiple continents, with major centers in the United States, various European countries, and increasingly in other regions as awareness of the condition grows. In the United States, specialized centers at major academic medical institutions often serve as trial sites, given the expertise required to safely manage patients with this complex condition. Patient eligibility typically requires genetic confirmation through ACVR1 gene testing, which became the gold standard for diagnosis following the gene’s discovery. Most trials enroll only patients above certain age cutoffs due to concerns about effects on normal skeletal development in very young children, though some studies specifically examine pediatric populations under carefully controlled conditions.^[3]

Most Common Treatment Methods

• Anti-inflammatory medications
  • Corticosteroids prescribed during acute flare-ups to reduce muscle inflammation and swelling
  • Short-term courses aimed at minimizing the severity of heterotopic bone formation
  • Dosing individualized based on flare-up location and severity
• Preventive care strategies
  • Avoiding trauma to soft tissues through careful activity selection and fall prevention
  • Respiratory exercises and singing to maintain chest wall mobility
  • Water-based exercise programs that allow movement without impact risk
  • Strict avoidance of passive range of motion exercises and invasive medical procedures
• Targeted molecular therapy (experimental)
  • Palovarotene, a retinoic acid receptor gamma agonist tested in clinical trials
  • Works by interfering with cartilage formation that precedes abnormal bone development
  • Aims to reduce new heterotopic bone volume during and after flare-ups
  • Currently under investigation in Phase II and III trials internationally
• Genetic medicine approaches (early research)
  • Antisense oligonucleotide therapy to reduce production of mutated ACVR1 protein
  • Uses specially designed genetic molecules that target messenger RNA
  • Currently in Phase I safety testing
• Antibody-based treatments (investigational)
  • Monoclonal antibodies designed to neutralize activin A protein
  • Aims to prevent inappropriate activation of the mutated ACVR1 receptor
  • Delivered by injection or infusion in early-phase clinical trials
• Supportive care interventions
  • Nutritional support when jaw involvement impairs eating
  • Assistive devices adapted for daily living activities
  • Home modifications to accommodate progressive mobility limitations
  • Respiratory support when rib cage ossification restricts breathing